Eli Lilly + Longevity-cluster v1 — retatrutide TRIUMPH-1 catalyst

TL;DR (honest verdict)

LLY is the cleanest publicly-tradable expression of the GLP-1-class metabolic-health franchise, and a defensible anchor for a NEW longevity-thesis cluster. TRIUMPH-1 (2026-05-21) showed retatrutide hitting 28.3% mean weight loss at 12mg / 80 weeks and 30.3% in the high-BMI extension at 104 weeks, materially above tirzepatide and semaglutide. Q1 2026 already proved Mounjaro/Zepbound are doing the work: combined $12.8B in a single quarter, +56% revenue growth. Recommended action: paper-trade a 2-name longevity cluster (LLY + VKTX) at $3,500 notional combined on 2026-05-22 open; defer real-money sleeve framing pending founder click-through. Real-money sleeve sized at 2-4% of liquid ($16k-$32k against $799k snapshot), explicitly under elon-verse v2's 5%/$40k locked allocation so the two bets do not compete.

Calibration callouts (load-bearing, applied per feedback_calibrate_overconfidence):

• LLY at $1,004 / 35x trailing P/E is NOT cheap. It's priced for execution. Multiple compression is the load-bearing bear risk, not pipeline failure.
• GLP-1-as-longevity-drug framing is partially supported (cardiovascular MACE, kidney protection, all-cause mortality meta-analyses) and partially extrapolation (Alzheimer's EVOKE just FAILED Nov 2025; "longevity drug" is too strong).
• Smart-money corroboration for THIS pick is unknown — RDCO's current 8-manager tracked set has zero biotech specialists. This is a smart-money-blind bet until the watch is expanded.
• LLY single-name concentration risk: retatrutide pricing, GLP-1 supply normalization, and tirzepatide competitive response from oral pills + Viking + others are all real.

The thesis

LLY captures the most defensible economics in the GLP-1 metabolic-health franchise because (a) tirzepatide is already at scale and outpacing semaglutide on weight loss + volume, (b) retatrutide just outperformed tirzepatide in phase 3 with bariatric-surgery-class results, (c) the oral GLP-1 (orforglipron) is the only credible Big-Pharma oral pill in the pipeline, and (d) the metabolic-health franchise is structurally adjacent to longevity outcomes via documented cardiovascular, renal, and all-cause-mortality benefits. The bet is NOT "GLP-1s cure aging" — it's "GLP-1s are the first mass-market chronic-disease franchise that meaningfully reduces all-cause mortality, and LLY owns the cleanest execution path through 2030." Longevity-cluster framing is correct because the binding-constraint is manufacturing + IP-defensibility around peptide injectable scale, which Lilly + Novo already won.

Bull case (structural argument)

The binding constraint: Peptide injectable manufacturing capacity + IP-defensibility around the GLP-1 receptor family. Lilly + Novo built the moat; everyone else is years behind on scale. This is a Snowflake-style consumption-ramp where the underlying compute layer is GMP peptide capacity, and Lilly spent 2023-2025 buying it (Lebanon IN, Concord NC, Pleasant Prairie WI, Ireland expansion).

Demand-side anchors:

• Q1 2026 Mounjaro $8.7B (+125% YoY) + Zepbound $4.16B (+80% YoY US) = $12.8B combined in a single quarter. Annualizing crudely puts the franchise on $50B+ run-rate.
• Total 2030 LLY revenue forecasts at $113B (Evaluate) with $62B from Mounjaro/Zepbound + $12.7B from orforglipron oral.
• US obesity prevalence ~42% adults + ~20% of adults eligible for GLP-1 by clinical criteria = sustained demand for a decade+.
• GLP-1 TAM 2030 estimates range $95B-$157B depending on source; oral GLP-1 alone projected at $22B (Goldman) with Lilly's orforglipron at ~60% share / $13.6B.

Retatrutide differential (the catalyst): TRIUMPH-1 (2026-05-21, n=2,339, 80 weeks) — 12mg dose hit 28.3% mean weight loss vs 2.2% placebo; 45.3% of participants hit >=30% weight loss (bariatric-surgery class); high-BMI extension hit 30.3% at 104 weeks. Discontinuation similar to placebo (no tolerability surprise). vs comparators: tirzepatide topped out ~22-23% in SURMOUNT; semaglutide ~15-17% in STEP. Retatrutide is the first non-surgical intervention reliably crossing the 25-30% weight-loss threshold. Lilly plans TRIUMPH-2 (T2D + obesity) and TRIUMPH-3 (CVD + obesity) reads later in 2026.

Pipeline beyond GLP-1: Kisunla / donanemab (Alzheimer's amyloid plaque clearance, FDA approved July 2024, now key product, EC approved Sept 2025, expanding into Japan/China/UK/etc); oncology (Verzenio + ongoing); immunology pipeline; Pfizer/Boehringer collabs. The Alzheimer's wing is the only public-pharma play on disease-modifying anti-amyloid therapy after Biogen exited Aduhelm.

Locked tickers (this thesis):

NVO deliberately excluded. CagriSema failed REDEFINE-4 non-inferiority vs tirzepatide on 2026-02-23; stock down ~56% from highs to ~$36 by March; Wegovy losing US share (LLY now >60%). The pill reversal narrative is real but the bet shape is "is Novo cheap enough?" not "is Novo the cleanest longevity vehicle?" — different thesis. Revisit only if NVO trades sub-$30 with a confirmed pipeline catalyst.

Bear case (devil's advocate — self-applied, no fresh-eyes sub-sub-agent on depth-1)

LLY is priced for perfection. $1,004 / ~35x trailing / ~27x forward — implies sustained 20-25% earnings growth for 3+ years. Any GLP-1 pricing pressure (Medicare negotiation, Wegovy pill driving US discounting, manufacturing supply normalization closing the demand>supply premium) compresses the multiple. A move from 27x forward to 20x forward = ~26% drawdown on multiple alone, even if estimates hold.

The "longevity drug" framing is partially marketing. EVOKE / EVOKE+ (semaglutide for early Alzheimer's, n=3,808 combined, 156 weeks) FAILED its primary endpoint in November 2025. Biomarkers improved, CDR-SB did not. This is the cleanest test of the "GLP-1 as neuroprotective longevity intervention" claim to date and it came back negative for clinical endpoints. The cardiovascular and renal benefits are real (SELECT, FLOW); the cognitive/dementia benefits are extrapolation that just failed. Anyone selling the LLY thesis as "longevity drug" needs to discount that.

Retatrutide is not a moat. It's a stronger drug. Three years from now Viking VK2735, Roche, Pfizer oral, Amgen MariTide, and Novo's next-gen are all in market. The 30% weight-loss number is the new ceiling not the new floor. Pricing power compresses.

Smart-money does NOT corroborate. The vault's 8-manager tracked set (Druckenmiller, Marathon, Tepper, Berkshire, Akre, Tiger Global, ARK, Gardner Russo Quinn) has essentially zero LLY conviction. ARK is technology/genomic-revolution oriented, not metabolic-health. This is a smart-money-blind bet, structurally similar to elon-verse v2's "7 of 8 silent" pattern. The risk is being early on a thesis where the smart-money-blind explanation is "they see something I don't" not "they haven't caught up yet."

Patent cliff math. Tirzepatide composition-of-matter patent runs to 2036-ish in major markets; biosimilars are a 2034+ concern but pricing pressure starts earlier from formulary negotiation. The 2030 $62B Mounjaro/Zepbound number assumes the franchise stays defended through then.

Cross-domain translation (load-bearing)

This is structurally like the Snowflake credit-consumption ramp circa 2020-2022 applied to peptide manufacturing. A new compute substrate (in this case GMP peptide injectable + soon oral peptide) hits a demand wall that exceeds supplier capacity. ASPs hold elevated while supply catches up over 2-4 years. The supplier with the largest pre-built capacity captures disproportionate share, and the moat is the manufacturing-investment lag — competitors take 3-5 years to bring greenfield peptide capacity online with the same quality controls. Lilly spent $20B+ on capex in 2023-2025 specifically to win this race.

The disanalogy: unlike cloud compute, peptide drugs face patent cliffs and biosimilar competition that compute platforms don't. The Snowflake comp works for 2026-2030; after 2032, the analog breaks down and the thesis transitions to "does Lilly have the pipeline replacement when tirzepatide goes off-patent."

Founder's data-engineering muscle should ratify: this is the "build the data warehouse before demand fully arrives, capture the consumption ramp, then defend with switching costs and integrated tooling" pattern. Lilly's switching costs are the manufacturing-quality-validation + payor-formulary placement + physician-prescription habit stack — not as deep as Snowflake's data-gravity moat, but real for 5-7 years.

Longevity-cluster framing (NEW)

Proposal: launch longevity-v1 as the 6th thesis bucket alongside memory, power, elon-verse, nvidia-supply-chain, nvidia-adjacent. Rationale: founder's strategic-direction signal (AI/compute + longevity = the two fast-growth Moonshots verticals); RDCO has zero pharma/biotech exposure currently; longevity is structurally orthogonal to AI/compute concentration risk (different end-markets, different regulatory regimes, different demand drivers).

Cluster composition (proposed):

LLY's position in cluster: Best vehicle for the metabolic-health longevity wedge specifically. NOT the best vehicle for the epigenetic reprogramming / cellular reset / senolytics wedges (those are private — Altos, Retro, NewLimit, Life Biosciences — none investable for founder per the existing longevity-roster file). For investable public-equity longevity exposure, LLY is the dominant choice today; VKTX is the asymmetric add.

Comparison vs index alternatives: XBI (SPDR S&P Biotech ETF, equal-weight ~120 names) and IBB (iShares Biotech ETF, market-cap weighted ~270 names). Both dilute the metabolic-health thesis with general biotech beta. For a conviction-driven longevity bet, single-name LLY + VKTX is the cleaner expression. Revisit ETF route only if the cluster scales beyond 2 names.

Existing vault context: 01-projects/investing/candidates/longevity-roster-2026-05.md exists (Diamandis-sourced, 2026-05-13). Useful as universe map but heavily Diamandis-vested. This thesis stays grounded in publicly-tradable names with primary-source financial data, not the Diamandis private-roster narrative.

Smart-money tracking gap (founder-flagged)

The current tracked-investor set at 01-projects/investing/anchors/smart-money/ is 8 managers: Druckenmiller (Duquesne), Marathon Asset, Appaloosa (Tepper), Berkshire, Akre, Tiger Global, ARK, Gardner Russo Quinn, plus Congress (Quiver Quant). Zero are biotech-specialists. ARK has genomic-revolution exposure but is tech-thematic, not pharma-fundamental.

Recommended additions to /investing:smart-money-watch (3 specialists, ranked by fit):

1. Baillie Gifford — Long-term growth philosophy, 10+ year holding periods, demonstrably long-only (mutual fund structure, no shorting/leverage). Has held Moderna, Alnylam, Recursion, Ginkgo Bioworks, Intuitive Surgical, Insulet across funds in 2025. The healthcare exposure in Long Term Global Growth + US Equity Growth funds is the cleanest "patient capital + growth biotech" signal among long-only managers. Verdict: top-priority add. Files NPORT-P quarterly (mutual fund equivalent of 13F).

2. Baker Bros. Advisors — Pure-play biotech specialist long fund. Files 13F. Has historically held large positions in clinical-stage biotechs that converted to multi-bagger commercial-stage. Whether they qualify as "long-only positive-sum" is the verification question — they're concentrated long-fund (not market-neutral, not shorting) but biotech specialists can be quasi-binary on trial outcomes. Verdict: add with caveat that biotech-specialist 13F signals are higher-variance than diversified long-only managers; weight 13F signal half-strength vs Druckenmiller-class.

3. Vanguard Health Care Fund (VGHCX) — Actively-managed mutual fund (Wellington sub-advised, Jean Hynes lead PM), $50B+ AUM, long-only by mandate, decades-long track record of healthcare long. Files quarterly. Not a fast-money mover but the "is the sector setting up?" signal from the largest active long-only healthcare PM is high-quality corroboration. Verdict: add as the slow-signal anchor; rotation IN to LLY or sector ETFs from VGHCX is a confirming signal, not a leading one.

Deliberately NOT recommended: Perceptive Advisors, RA Capital, OrbiMed, Avoro, Casdin — these are hedge funds with short books, leverage, or concentrated binary biotech bets. Skill spec requires "long-only positive-sum"; these don't qualify cleanly. Surface them at the next skill-spec revision if founder wants to broaden the universe.

Implementation: Either (a) extend the smart-money-watch skill set to add these three at the next skill-update window, or (b) one-shot back-fill against last 4-8 quarters of NPORT-P / 13F for these three to baseline their LLY / biotech positioning before deploying real money on this thesis. Recommended: option (b) before real-money deploy on longevity-v1.

GLP-1-as-longevity-drug evidence (calibrated)

Strong evidence (mechanism-confirmed, primary endpoint hit, peer-reviewed):

• SELECT trial — semaglutide 2.4mg, n=17,604, established CVD + obesity without diabetes. 20% reduction in MACE (CV death + nonfatal MI + nonfatal stroke). Effect emerged by day 20, statistically significant by day 86. Published NEJM 2023. Subsequent prespecified analyses confirmed reduction independent of weight loss, hospital admission reduction, kidney-outcome benefit, all-cause mortality HR 0.81 (95% CI 0.71-0.93). This is the most load-bearing positive evidence.

• FLOW trial — semaglutide 1.0mg, n=3,533, T2D + CKD (eGFR 50-75, UACR 300-5000). 24% reduction in composite kidney outcomes + CV events + all-cause death. Published NEJM 2024 (391:109-21). Median follow-up 3.4 years. Trial stopped early for efficacy.

• Meta-analyses (2024-2025) — multiple systematic reviews (European Heart Journal, EHJ-CV Pharmacotherapy) showing all-cause mortality OR 0.87 (95% CI 0.82-0.94) across GLP-1 RA trials in T2D + obesity populations. In T2D + HFrEF subgroup, all-cause mortality HR 0.62 over 5 years vs DPP4-inhibitor controls. Swiss Re actuarial modeling projects 4-6.4% all-cause US mortality reduction by 2045 attributable to GLP-1 uptake.

• Mechanism plausibility — anti-inflammatory effects (hsCRP reduction), improved endothelial function, reduced visceral adiposity, improved insulin sensitivity. These are independently documented; the "GLP-1 as cardiometabolic anti-aging intervention" framing is mechanistically supported even when the longevity-extrapolation isn't.

Hopeful narrative / unproven (treat as marketing):

• Alzheimer's prevention — EVOKE / EVOKE+ (semaglutide, n=1,855 + n=1,953, 156 weeks, oral 14mg) FAILED primary endpoint in November 2025. CDR-SB unchanged vs placebo. Biomarkers improved but no clinical benefit. Lancet publication 2026. This is the most important recent negative result and it directly contradicts the "GLP-1 as longevity drug for cognition" pitch. Anyone making this claim post-Nov 2025 is selling against published phase 3 data.

• Parkinson's prevention — observational signals only; no positive phase 3 to date.

• Cancer prevention — observational signals (mostly retrospective cohort studies on obesity-associated cancers); confounded by weight-loss effect; no GLP-1 specific phase 3.

• General "anti-aging" — no direct evidence. The mortality reduction is plausibly explained by cardiovascular + metabolic + renal mechanisms, not by aging biology per se.

Bottom line for the thesis: The GLP-1 cardiometabolic story is robust enough to underwrite the LLY revenue thesis. The "longevity drug" extension is partially supported for mortality reduction in high-risk populations, NOT supported for cognition (EVOKE failure), and unproven for general aging. Position the thesis as "metabolic-health franchise with documented mortality benefit in high-risk populations" — not as "longevity drug." Founder should be skeptical of any pitch (including from Diamandis-class sources) that overclaims the cognitive / anti-aging story.

Demand-side anchors (observable signals confirming thesis)

1. LLY Q2 2026 earnings (late July 2026) — Mounjaro/Zepbound run-rate continuation. Watch for: US Zepbound price erosion (compounding pharmacy + Novo pill pricing pressure), international Mounjaro acceleration, capex guidance.
2. TRIUMPH-2 readout (2026 H2) — retatrutide in T2D + obesity. Confirms or breaks the retatrutide premium.
3. TRIUMPH-3 readout (2026 H2 or 2027) — retatrutide in CVD + obesity. Confirms or breaks the "next-gen GLP-1 also has cardio benefit" extension.
4. Orforglipron NDA filing / FDA action — Lilly's oral GLP-1. 2026 phase 3 reads complete; NDA expected 2026 H2 with approval 2027. The first oral GLP-1 with injectable-class efficacy = $13B+ market wedge.
5. Retatrutide NDA / approval window 2027-2028 — the primary catalyst this thesis is positioned for.
6. Smart-money rotation — once VGHCX / Baillie Gifford / Baker Bros tracking is back-filled, watch for net-buying in LLY across the three. Net-selling = bear signal.
7. VKTX VANQUISH-1/2 Q3 2026 readouts — binary catalysts for the secondary position.

Disqualifying conditions (what archives the thesis)

• LLY trades below $750 on multiple compression with no underlying business deterioration → thesis still works, just sized larger (NOT a disqualifier, an entry-improvement)
• TRIUMPH-2 or TRIUMPH-3 fails primary endpoint → retatrutide premium evaporates; thesis downgrades from "anchor" to "Mounjaro/Zepbound run-out trade"
• US Medicare negotiation includes Mounjaro/Zepbound at unfavorable price → primary disqualifier on the multiple expansion case
• Orforglipron oral fails or is heavily restricted on safety → removes 2030 $12.7B optionality
• Smart-money back-fill (Baillie Gifford / Baker Bros / VGHCX) shows persistent net-selling of LLY across 4+ quarters → primary disqualifier on the bull case
• Lilly capex execution problem (manufacturing recall, FDA warning letter on a peptide site) → primary disqualifier on the moat claim
• A credible #3 player (Viking, Roche, Amgen MariTide) hits market with 25%+ weight loss data at materially lower price → margin compression > volume growth; multiple compresses

Phase markers

Phase 1 (now → Q4 2026): Entry + corroboration

• Action: paper-deploy LLY 2R + VKTX 0.5R on 2026-05-22 open
• Required for advance: smart-money watch expansion (Baillie Gifford + Baker Bros + VGHCX added; back-fill 4-8 quarters); 1 of 3 confirms LLY or sector overweight
• Required for advance: TRIUMPH-2 or TRIUMPH-3 readout positive
• Re-eval: end of Q3 2026 after VKTX VANQUISH-1/2 reads
• Phase-2 trigger: 2 of (smart-money confirms / TRIUMPH-2 hits / TRIUMPH-3 hits / orforglipron NDA accepted) all firing

Phase 2 (Q4 2026 → Q2 2027): Real-money sleeve initiation

• Action: founder click-through on real-money sleeve. Start at 1-2% of liquid NW ($8k-$16k) in LLY single-name via Schwab. Stage across 3 months.
• Required for advance: retatrutide NDA accepted by FDA; orforglipron approval; no material smart-money exit
• Phase-3 trigger: retatrutide FDA approval (expected 2027-2028)

Phase 3 (2027-2028+): Accumulation + cluster expansion

• Action: scale LLY sleeve to 3-4% of liquid NW ($24k-$32k). Add second cluster name based on Phase 1 watchlist evolution.
• Re-eval: quarterly
• Exit triggers below.

Position sizing

Paper (today's deploy): LLY 2R / $10,000 notional + VKTX 0.5R / $2,500 notional = $12,500 total against $41,250 cash / $143k buying power. Well within paper account headroom.

Real-money sleeve (proposed, NOT deploying tonight): 2-4% of liquid NW ($16k-$32k against $799k Monarch snapshot 2026-05-20). Initial real-money tranche at 1-2% / $8k-$16k after Phase 1 corroboration. Staged 30/30/20/20 across T1 entry / T2 30d / T3 90d / T4 180d.

Explicit non-conflict with elon-verse v2: Elon-verse v2 locked 5% / $40k 2026-05-20. Longevity-v1 proposed at 2-4% / $16k-$32k. Combined max: 9% / $72k. Both sleeves draw from Schwab + Wealthfront pools that have ~$200k+ deployable. No conflict.

Why not bigger: smart-money-blind status, single-name concentration risk, multiple-compression risk. Per feedback_calibrate_overconfidence: under-claim. The 2-4% band reflects "high conviction in thesis structure, lower conviction in entry timing." Move to 5-7% only after Phase 2 corroboration completes.

Exit rules

• Multiple compression exit: LLY forward P/E expands to >35x without underlying business acceleration → trim 25% of position
• Disqualifier-driven exit: Any disqualifying condition firing → archive thesis; close position over 4 weeks to minimize market impact
• Stop loss: Drawdown >35% from entry-average with no concurrent thesis confirmation → exit fully
• Profit-taking trim: +75% from entry-average → trim 25%; +150% → trim another 25%
• Time-based re-eval: Quarterly per EPS + key trial readouts; annual full thesis re-write

Targeting-system filter (per feedback_targeting_system_prioritization_filter)

• Targeting YES. Longevity is one of two founder-named fast-growth verticals (with AI/compute). Cluster fills the AI-only concentration gap in current investing book. Anchored to a specific niche (metabolic-health franchise with documented mortality data) and a specific bottleneck (peptide manufacturing capacity + IP).
• Instrumentation YES. Quarterly LLY earnings + TRIUMPH-2/3 + VKTX VANQUISH + orforglipron NDA = dense observable catalyst calendar. Smart-money watch needs expansion (gap surfaced above) but the corrective is concrete.
• Tools YES. LLY + VKTX are large-cap NYSE/NASDAQ liquid. Schwab + Alpaca paper-tracking both work cleanly. No accreditation needed. No pre-IPO access friction.
• Feedback loop PARTIALLY. Catalyst calendar is dense (good); smart-money corroboration set is currently empty (bad — addressed by recommended additions). Founder lacks lived domain experience here (vs AI/compute where he's an operator) — calibration needs to lean MORE on under-claiming, not less.

Filter verdict: ANCHORED, with explicit caveat that smart-money watch expansion is a Phase-1-blocker for real-money advancement.

Sources (primary, cited inline above)

1. TRIUMPH-1 phase 3 results press release — Lilly investor relations, 2026-05-21. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average
2. Lilly Q1 2026 earnings 8-K — SEC EDGAR, filed 2026-04-30. https://www.sec.gov/Archives/edgar/data/0000059478/000005947826000043/q126lillysalesandearningsp.htm
3. SELECT trial primary results — Lincoff et al., NEJM 2023. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. n=17,604.
4. FLOW trial primary results — Perkovic et al., NEJM 2024;391:109-21. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. n=3,533.
5. EVOKE / EVOKE+ trial results (negative) — Lancet 2026 publication; topline released November 2025. Oral semaglutide in early symptomatic Alzheimer's disease. Combined n=3,808. Failed primary endpoint.
6. GLP-1 RA mortality meta-analysis — multiple 2024-2025 systematic reviews in European Heart Journal + EHJ-CV Pharmacotherapy. All-cause mortality OR 0.87.
7. Viking Therapeutics VANQUISH-1/2 enrollment + VENTURE phase 2 publication — Viking IR + Obesity journal Jan 2026. VK2735 phase 3 reads expected Q3 2026.
8. Novo Nordisk Q1 2026 + REDEFINE-4 CagriSema failure — Novo IR 2026-05-06; REDEFINE-4 readout 2026-02-23.
9. Evaluate 2030 LLY revenue forecast — $113B total, $62B Mounjaro/Zepbound.
10. Goldman Sachs oral GLP-1 market forecast — $22B 2030 oral market; Lilly orforglipron ~60% share.
11. ICER GLP-1 obesity draft report 2025 — value-based pricing context.
12. Vault longevity roster — 01-projects/investing/candidates/longevity-roster-2026-05.md, Diamandis-sourced May 2026. Used for cluster framing context.
13. Vault smart-money tracked set — 01-projects/investing/anchors/smart-money/ 8 managers; gap surfaced above.

Related

• [[../candidates/longevity-roster-2026-05]] — Diamandis universe map (paid-discovery caveat)
• [[2026-05-20-elon-verse-v2]] — sibling thesis; confirms multi-bucket sleeve coexistence is the model
• [[2026-05-12-innermost-loop-ai-infrastructure]] — AI/compute cluster (parallel vertical)
• [[~/.claude/projects/-Users-ray/memory/feedback_calibrate_overconfidence]]
• [[~/.claude/projects/-Users-ray/memory/feedback_targeting_system_prioritization_filter]]
• [[~/.claude/projects/-Users-ray/memory/feedback_paper_trade_deploy_authorization]]
• [[~/.claude/projects/-Users-ray/memory/feedback_alpaca_paper_opg_unreliable]]
• [[../README]] — parent investing project

Open questions for founder

1. Greenlight longevity-v1 as a permanent thesis bucket? Or treat this as a one-shot LLY+VKTX bet without cluster framing?
2. Smart-money watch expansion priority? (a) extend the skill now to add Baillie Gifford + Baker Bros + VGHCX, or (b) keep the skill stable and back-fill these three manually before real-money deploy?
3. Real-money sleeve sizing band? 2-4% / $16k-$32k is the conservative recommendation given smart-money-blind status. Founder can move higher (4-7% range) if conviction explicitly higher than the calibrated bull case. Below 2% likely not worth the operational overhead.
4. Schwab vs Wealthfront brokerage routing when real-money tranche activates? (LLY + VKTX are both large-cap liquid — either works; defaults to whichever has fresher dry powder.)

Changelog

• 2026-05-21 17:55 ET (v1) — Initial framing. Catalyst: TRIUMPH-1 phase 3 readout same day. Paper-deploy proposed for 2026-05-22 open per Alpaca-paper-OPG-unreliable memory. NEW longevity-v1 cluster proposed. Smart-money gap surfaced; 3 specific additions recommended (Baillie Gifford, Baker Bros, VGHCX). EVOKE failure (Nov 2025) explicitly applied as bear-side calibration against the "longevity drug" framing. Real-money deploy NOT proposed; pending founder click-through on /decisions/ page (deferred to a follow-up build).